Cerebrolysin is a peptidergic compound prepared based on free amino acids and peptide molecules of very low molecular weight that has been established as a therapeutic option for the treatment of injuries caused in the central nervous system (CNS) by a traumatic process, based on its neurotrophic, neurogenesis, neuroprotective and neuronal reactivation capacity, evidenced by positive changes in post-traumatic functional and cognitive recovery.   Cerebrolysin has been shown to produce neuronal growth and decrease apoptotic neuronal death and thus has the potential to reduce the complications associated with traumatic injuries. The use of cerebrolysin as a therapeutic agent has been studied through clinical trials developed in Russia. The benefits associated with the use of cerebrolysin after traumatic damage can be associated with its capacity for cell reactivation, the decrease in neuronal death with inhibition of cell apoptosis, and increased production of new neurons stimulated by its action. Similar to endogenous neurotrophic factors, decreased toxicity and free radical release and decreased damage to the blood-brain barrier with the recovery of areas of structural damage.